125 related articles for article (PubMed ID: 38527505)
1. [Genotype-phenotype analysis of Fabry disease caused by GLA gene variation in a pedigree].
Ge ZH; Lu ZH; Pan XD; Lai TT; Yang MJ; Yang HQ; Zhang HB; Li GY; Dai ZQ; Mao JH
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):345-350. PubMed ID: 38527505
[No Abstract] [Full Text] [Related]
2. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).
Hwu WL; Chien YH; Lee NC; Chiang SC; Dobrovolny R; Huang AC; Yeh HY; Chao MC; Lin SJ; Kitagawa T; Desnick RJ; Hsu LW
Hum Mutat; 2009 Oct; 30(10):1397-405. PubMed ID: 19621417
[TBL] [Abstract][Full Text] [Related]
3. Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations.
Chien YH; Lee NC; Chiang SC; Desnick RJ; Hwu WL
Mol Med; 2012 Jul; 18(1):780-4. PubMed ID: 22437327
[TBL] [Abstract][Full Text] [Related]
4. Genetic epidemiological study doesn't support GLA IVS4+919G>A variant is a significant mutation in Fabry disease.
Chiang HL; Wang NH; Song IW; Chang CP; Wen MS; Chien YH; Hwu WL; Tsai FJ; Chen YT; Wu JY
Mol Genet Metab; 2017 May; 121(1):22-27. PubMed ID: 28377241
[TBL] [Abstract][Full Text] [Related]
5. Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation.
Chien YH; Bodamer OA; Chiang SC; Mascher H; Hung C; Hwu WL
J Inherit Metab Dis; 2013 Sep; 36(5):881-5. PubMed ID: 23109060
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
[TBL] [Abstract][Full Text] [Related]
7. The Fabry disease-causing mutation, GLA IVS4+919G>A, originated in Mainland China more than 800 years ago.
Liang KH; Lu YH; Niu CW; Chang SK; Chen YR; Cheng CY; Hsu TR; Yang CF; Nakamura K; Niu DM
J Hum Genet; 2020 Jul; 65(7):619-625. PubMed ID: 32246049
[TBL] [Abstract][Full Text] [Related]
8. Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease.
Chang WH; Niu DM; Lu CY; Lin SY; Liu TC; Chang JG
PLoS One; 2017; 12(4):e0175929. PubMed ID: 28430823
[TBL] [Abstract][Full Text] [Related]
9. Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G→A).
Lin HY; Huang CH; Yu HC; Chong KW; Hsu JH; Lee PC; Cheng KH; Chiang CC; Ho HJ; Lin SP; Chen SJ; Lin PK; Niu DM
J Inherit Metab Dis; 2010 Oct; 33(5):619-24. PubMed ID: 20821055
[TBL] [Abstract][Full Text] [Related]
10. Late-onset and classic phenotypes of Fabry disease in males with the
Valtola K; Hedman M; Kantola I; Walls S; Helisalmi S; Maria M; Raivo J; Auray-Blais C; Kuusisto J
Open Heart; 2023 Mar; 10(1):. PubMed ID: 36927868
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease.
Dai X; Zong X; Pan X; Lu W; Jiang GR; Lin F
Orphanet J Rare Dis; 2022 Jun; 17(1):237. PubMed ID: 35725559
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Novel GLA Gene Mutation, p.Ile239Met, in Fabry Disease With a Predominant Cardiac Phenotype.
Csányi B; Hategan L; Nagy V; Obál I; Varga ET; Borbás J; Tringer A; Eichler S; Forster T; Rolfs A; Sepp R
Int Heart J; 2017 May; 58(3):454-458. PubMed ID: 28496025
[TBL] [Abstract][Full Text] [Related]
13. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.
Sadasivan C; Chow JTY; Sheng B; Chan DKH; Fan Y; Choi PCL; Wong JKT; Tong MMB; Chan TN; Fung E; Kam KKH; Chan JYS; Chi WK; Paterson DI; Senaratne M; Brass N; Oudit GY; Lee APW
PLoS One; 2020; 15(9):e0239675. PubMed ID: 32987398
[TBL] [Abstract][Full Text] [Related]
14. A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene.
Tuttolomondo A; Duro G; Pecoraro R; Simonetta I; Miceli S; Colomba P; Zizzo C; Di Chiara T; Scaglione R; Della Corte V; Corpora F; Pinto A
Clin Biochem; 2015 Jan; 48(1-2):55-62. PubMed ID: 25281798
[TBL] [Abstract][Full Text] [Related]
15. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population.
Lin HY; Chong KW; Hsu JH; Yu HC; Shih CC; Huang CH; Lin SJ; Chen CH; Chiang CC; Ho HJ; Lee PC; Kao CH; Cheng KH; Hsueh C; Niu DM
Circ Cardiovasc Genet; 2009 Oct; 2(5):450-6. PubMed ID: 20031620
[TBL] [Abstract][Full Text] [Related]
16. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
[TBL] [Abstract][Full Text] [Related]
17. The D313Y variant in the GLA gene - no evidence of a pathogenic role in Fabry disease.
Hasholt L; Ballegaard M; Bundgaard H; Christiansen M; Law I; Lund AM; Norremolle A; Krogh Rasmussen A; Ravn K; Tumer Z; Wibrand F; Feldt-Rasmussen U
Scand J Clin Lab Invest; 2017 Dec; 77(8):617-621. PubMed ID: 29037082
[TBL] [Abstract][Full Text] [Related]
18. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
[TBL] [Abstract][Full Text] [Related]
19. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).
Liu HC; Lin HY; Yang CF; Liao HC; Hsu TR; Lo CW; Chang FP; Huang CK; Lu YH; Lin SP; Yu WC; Niu DM
Orphanet J Rare Dis; 2014 Jul; 9():111. PubMed ID: 25047006
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry.
Romani I; Sarti C; Nencini P; Pracucci G; Zedde M; Cianci V; Nucera A; Moller J; Orsucci D; Toni D; Palumbo P; Casella C; Pinto V; Barbarini L; Bella R; Scoditti U; Ragno M; Mezzapesa DM; Tassi R; Volpi G; Diomedi M; Bigliardi G; Cavallini AM; Chiti A; Ricci S; Cecconi E; Linoli G; Sacco S; Rasura M; Giordano A; Bonetti B; Melis M; Cariddi LP; Dossi RC; Grisendi I; Aguglia U; Di Ruzza MR; Melis M; Sbardella E; Vista M; Valenti R; Musolino RF; Passarella B; Direnzo V; Pennisi G; Genovese A; Di Marzio F; Sgobio R; Acampa M; Nannucci S; Dagostino F; Dell'Acqua ML; Cuzzoni MG; Picchioni A; Calchetti B; Notturno F; Di Lisi F; Forlivesi S; Delodovici ML; Buechner SC; Biagini S; Accavone D; Manna R; Morrone A; Inzitari D
J Neurol Sci; 2024 Feb; 457():122905. PubMed ID: 38295534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
